Health ❯ Healthcare ❯ Patient Outcomes

Progression-Free Survival

Overall Survival Treatment Efficacy Objective Response Rate ESR1 Mutations Response Rates Efficacy of Treatment Immune Fitness Treatment-naive Patients Efficacy Analysis Adverse Events Minimal Residual Disease Camizestrant Efficacy

FDA Clears Enhertu-Perjeta Combo for First-Line HER2-Positive Metastatic Breast Cancer

The decision follows phase 3 results showing a roughly 14-month median progression-free survival advantage over the THP regimen.

Tucatinib Added to First-Line HER2 Maintenance Prolongs Progression-Free Survival in Phase 3 Trial

Sacituzumab Govitecan Gains First-Line Ground in TNBC, Falls Short in Early HR+/HER2− Use

Pirtobrutinib Extends First-Line PFS vs BR and Shows Higher Response Rates Than Ibrutinib in CLL/SLL

Early Cilta-Cel Use Linked to Better Outcomes in Relapsed/Refractory Myeloma, ASH 2025 Data Show

FDA Approves Darzalex Faspro as First Therapy for High-Risk Smoldering Multiple Myeloma

Roche’s Giredestrant Plus Everolimus Extends PFS in Phase 3 evERA for ER-Positive, HER2-Negative Breast Cancer